Cargando…
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs...
Ejemplares similares
-
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
por: Cattaneo, Chiara, et al.
Publicado: (2022) -
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry
por: Marchetti, Monia, et al.
Publicado: (2023) -
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
por: Pagano, Livio, et al.
Publicado: (2022) -
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
por: Pagano, Livio, et al.
Publicado: (2022) -
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
por: Busca, Alessandro, et al.
Publicado: (2023)